(EMAILWIRE.COM, June 28, 2008 ) Denver, CO - LegalView, the number one site for everything and anything legal on the Internet, recently reported on a loophole that may potentially put homebuyers at risk for asbestos exposure. According to industry experts, most home inspectors omit asbestos checks when routinely checking a home prior to the home being purchased or sold. Because of this, many homeowners purchase asbestos-tainted homes without any knowledge of the toxicity that lies within the newly purchased home walls and flooring. Individuals who may be at risk for asbestos exposure should seek medical attention immediately to learn more and receive adequate mesothelioma information (http://mesothelioma.com/blog) to protect and prevent the condition from occurring. Additionally, it is advisable to locate a mesothelioma law firm (http://mesothelioma.legalview.com/find-mesothelioma-law-firm.aspx) that will have a plethora of experienced mesothelioma attorneys (http://mesothelioma.legalview.com) available to provide insight into developing a potential mesothelioma lawsuit (http://mesothelioma.legalview.com/mesothelioma-lawsuit-results.aspx).

The American Society of Home Inspectors (ASHI) only classifies asbestos under the category of mold, and, according to their Web site, refers individuals to the Center for Disease Control and Prevention (CDC) as well as the Environmental Protection Agency (EPA) for more information on what should be done if asbestos is found. While there is no known safe level of asbestos inhalation and exposure, this loophole may create a risk for millions of unknowing Americans who are in danger of asbestos toxicity. Individuals who feel they are living in an asbestos-tainted home should contact the CDC, EPA and medical professionals. Additionally, seeking out a mesothelioma attorney (http://mesothelioma.legalview.com) may help if the need for a mesothelioma lawsuit arises.

LegalView continues to remain the number one legal resource on the Web for all Americans to access freely and receive information on a range of topics including information on the ongoing Avandia investigation as well as information on the Chantix and Singulair risks.

Avandia, a prescription drug used to treat type 2 diabetes, has been linked to serious risks including an increased chance of suffering from a heart attack while on the drug or the possibility for early onset osteoporosis as well as a higher risk of bone fracture. LegalView recently revamped its Avandia information portal to provide the latest information on Avandia side effects (http://avandia.legalview.com) as well as the U.S. Food and Drug Administration (FDA) investigation of the drug.

While both Singulair and Chantix treat extremely different conditions, both made headlines recently for similar side effects. Chantix is a smoking cessation drug that was released in mid-2006, within a short period of time approximately three million Americans began taking the stop smoking aid. However, in late 2007, reports flooded the FDA's offices with individuals claiming Chantix side effects (http://chantix.legalview.com) were causing them to become depressed, moody, exude erratic and abnormal behavior as well as to have increased urges for suicidal thoughts and actions. Similarly, takers of Singulair, a drug used to treat asthma and severe allergies, began to express concern with Singulair risks (http://singulair.legalview.com), which included depression, suicidal thoughts and tendencies.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Contact Information:
LegalView
Katie Kelley
Tel: 720-771-3246
Email us